The precise contribution(s) of skin dendritic cells (DCs) to immune responses in the skin has not been well delineated. We developed an intradermal (i.d.) injection model in which CD8 þ T (OT-I) cells that express ovalbumin (OVA) peptide-specific TCRs (Va2/Vb5) are delivered directly to the dermis of transgenic (Tg) mice expressing OVA in the epidermis. After i.d. injection, these mice reliably develop skin graft-versus-host disease (GVHD) by day 7. To determine the relative contribution of Langerhans cells (LCs) to the ensuing GVHD-like reaction, we generated K14-OVA Â Langerin-diphtheria-toxin-receptor (Langerin-DTR) Tg mice to allow conditional ablation of LCs in the epidermis. To delineate the role of dermal DCs (dDCs) in the reaction, we also generated K14-OVA Tg chimeras using b 2 -microglobulin-deficient (b 2 m) congenic donor bone marrow cells. Dermal DCs in these mice cannot present OVA to autoreactive T cells (OT-I cells), whereas the LCs are antigen presentation-competent. Unexpectedly, OT-I cell injection into diphtheria toxin (DT)-treated b 2 m-K14ÀOVA Â Langerin-DTR Tg mice resulted in skin GVHD. Thus, in vivo, both LC and dDC appear to be dispensable for the induction of keratinocyte-directed, CD8-mediated effector immune responses. Furthermore and surprisingly, OVA-expressing epidermal cells depleted of LCs that could not initiate allogeneic epidermal lymphocyte reactions activated naive OT-I cells in vitro. These results indicate that keratinocytes may function as accessory cells competent to prime naive skin-reactive T cells.
INTRODUCTION
Dendritic cells (DCs) are the primary antigen-presenting cells (APCs) that mediate T-cell immunity and tolerance (Banchereau and Steinman, 1998; Hawiger et al., 2001; Probst et al., 2003) . In skin, it is thought that epidermal Langerhans cells (LCs) and dermal DCs (dDCs) serve this role by taking up antigen (Ag) in the periphery and acting as sentinels. In the immature state, DCs express low levels of surface costimulatory molecules and induce tolerance on interaction with naive T cells (Hawiger et al., 2001; Steinman and Nussenzweig, 2002; Probst et al., 2003) . After activation by pathogenic stimuli, skin DCs upregulate major histocompatibility complex II (MHC II), CD40, CD80, and CD86 molecules and migrate to the skin-draining lymph nodes (LNs) to prime naive T cells (Stoitzner et al., 1999; Hemmi et al., 2001; Carbone et al., 2004) . It has been suggested that LCs continuously migrate to the cutaneous LN to maintain tolerance to self-Ag; however, a series of recent studies have suggested that LCs may have an immunostimulatory function even in the steady state (Azukizawa et al., 2003; Mayerova et al., 2004; Shibaki et al., 2004) . Thus, the precise role of LCs in the induction of tolerance and immunity remains unclear. The role of dDCs has remained even more elusive.
Recent studies suggest several possibilities regarding the relative contributions of skin DCs (LCs and dDCs) to crosspresentation of skin-derived Ag, T-cell priming, viral immunity, and contact hypersensitivity (CHS). With regard to CHS, elimination of LCs repeatedly resulted in three outcomes: no effect, attenuation, and enhancement of CHS responses (Bennett et al., 2005; Kaplan et al., 2005; Kissenpfennig et al., 2005) . Despite varying results, each of these studies indicated that dDCs are sufficient to elicit a significant CHS response. However, the relative contributions of LCs and dDCs to the presentation of skin-associated protein Ag to CD8 þ T cells remain unclear. We previously described a systemic graft-versus-hostdisease (GVHD) model in which mice that expressed a membrane-bound form of ovalbumin (mOVA) regulated by a keratin 14 (K14) promoter developed weight loss and skin and esophageal lesions after intravenous (i.v.) transfer of autoreactive T cells (OT-I cells) (Shibaki et al., 2004) . To better understand the mechanisms underlying Ag presentation within the skin, we developed an intradermal (i.d.) injection model in which OT-I cells are delivered directly into the dermis of different lines of K14-OVA transgenic (Tg) mice and elicit localized GVHD reactions. To examine the role of LCs in this reaction, we generated K14-OVA Â Langerin-diphtheria-toxinreceptor (Langerin-DTR) double-Tg mice to allow conditional ablation of LCs after administration of diphtheria toxin (DT) (Bennett et al., 2005) . To determine the contribution of dDCs (and potential circulating DC precursors), we chimerized K14-OVA Tg mice with congenic b 2 -microglobulin-deficient (b 2 m) bone marrow cells to impair the presentation of OVA Ag through MHC class I molecules. Surprisingly, we determined that the elimination of epidermal LCs and/or the impairment of dDCs did not abrogate localized GVHD reactions in vivo. We also show that the elimination of LCs from the epidermis could abrogate mixed epidermal lymphocyte reactions (MELRs) but did not attenuate OT-I T-cell priming. These results indicate that keratinocytes can present self-Ag that is expressed in epidermis to naive CD8 T cells.
RESULTS

OVA mRNA expression level varies between the different lines of K14-OVA Tg mice
Five Tg mouse lines that express either soluble (K14-sOVA(5), , and K14-sOVA(17) Tg) or membrane-bound (K14-mOVA(3) and K14-mOVA(6) Tg) forms of OVA in epidermis were established. OVA mRNA expression levels were quantified by real-time reverse transcription-PCR in ears ( Figure 1 ) and trunk skin (data not shown). K14-mOVA(6) Tg mice develop systemic GVHD after i.v. transfer of OT-I cells manifested by histological signs and 30% weight loss by day 7 (Shibaki et al., 2004) . Tg mice that express the highest level of OVA mRNA (Figure 1 ) developed more severe disease and died by days 4-5 after adoptive transfer of OT-I cells (data not shown). In contrast to the K14-mOVA(6) and K14-sOVA(15) Tg mice, other strains (K14-mOVA(3), K14-sOVA(5), and K14-sOVA(17) Tg) that expressed lower levels of OVA mRNA did not develop systemic GVHD after i.v. transfer of OT-I cells (data not shown). Thus, the development of systemic GVHD reactions after i.v. transfer of OT-I cells correlates well with the level of OVA mRNA expression.
All lines of K14-OVA Tg mice develop localized GVHD after i.d. injection of OT-I cells To additionally investigate the mechanism of GVHD in skin, 2 Â 10 6 OT-I cells were injected i.d. into the ears of all lines of K14-OVA Tg mice. After i.d. injection, skin GVHD developed in all mice manifested on day 7 with widespread vacuolar changes, apoptosis of keratinocytes, and lymphocytic infiltration of the dermis and epidermis (Figure 2b -f). In contrast, i.d. injection of the same number of OT-I cells into the ears of control C57BL/6 (syngeneic) (Figure 2a ) and BALB/c (allogeneic) (data not shown) mice did not cause skin GVHD. Injection of purified control CD8 þ C57BL/6 T cells into the ears of K14-mOVA(6) Tg and C57BL/6 mice also did not cause local reactions (data not shown). Thus, localized GVHD reactions were specific for OT-I cells encountering OVA Ag within the skin of all K14-OVA Tg mouse lines, independent of the level of OVA mRNA expression, or susceptibility of lines to develop systemic GVHD after i.v. transfer of OT-I cells.
I.d. injection of OT-I cells causes activation of LCs within the skin on day 2 and GVHD-like changes by day 3
Histologically, GVHD reactions in skin after i.d. injection were much more severe than previously observed in the systemic GVHD model (Shibaki et al., 2004) . To understand the mechanism of this local reaction, epidermal sheets were stained with antibodies against MHC II molecules on day 2 after i.d. injection of 2 Â 10 6 OT-I cells in 20 ml of phosphatebuffered saline (PBS). Clusters of enlarged LCs with elongated dendrites were evident, suggesting maturation in the epidermis (Figure 3b ). Maturation of LCs was also evident after injection of 20 ml of PBS alone, suggesting that the i.d. injection itself was sufficient to elicit maturation of LCs (Figure 3c) .
A time-course experiment revealed that i.d. injection of 2 Â 10 6 OT-I cells consistently resulted in vacuolar changes on day 3 with occasional apoptosis of keratinocytes (Figure 3d-g ). By day 4, a complete GVHD reaction could be consistently identified (Figure 3g) . Thus, the onset of GVHD occurred soon after the activation of LCs within the epidermis. The sequence and kinetics of events suggest that the maturation of LCs could provide the requisite costimulatory signals that induce early priming of OT-I cells that elicit rapid and severe local GVHD.
I.d. injection of OT-I cells induces expression of MHC II molecules by keratinocytes
As previously described for acute GVHD reactions in skin, we examined whether MHC II molecules were expressed on Ovalbumin (OVA) mRNA expression was quantified by real-time RT-PCR using total RNA extracted from the ears of all strains of K14-OVA Tg mice (-mOVA(3), -sOVA(5), -mOVA(6), -sOVA(15), and -sOVA(17)) and control C57BL/6 mice. All measurements were performed in triplicates and normalized to endogenous levels of b-actin. Standard error bars are included. The notations m and s indicate whether the epidermal OVA is targeted to the keratinocyte membrane (m) or is in soluble (s) form. keratinocytes after i.d. injection of OT-I cells (Breathnach and Katz, 1983; Breathnach et al., 1986) . After injection of OT-I cells, epidermal sheets stained for MHC II on day 4 showed widespread keratinocyte MHC II expression (Figure 3i ). This was not yet obvious on day 2 (Figure 3b ). It has been previously reported that systemic administration of IFN-g to normal mice caused similar MHC II expression by keratinocytes . Whether the response of keratinocytes in the localized GVHD reaction is because of IFN-g secretion by effector OT-I cells is uncertain. However, i.d. injection of 100,000 U of murine IFN-g (mIFN-g) into C57BL/6 mice daily for 2 days showed similar keratinocyte MHC II expression on day 3 (Figure 3k ). These results indicate that the development of GVHD reactions in skin coincided with keratinocyte MHC II expression, as reported in other mouse models of GVHD (Breathnach and Katz, 1983; Breathnach et al., 1986) .
OT-I cells proliferate and become activated within the dermis of the K14-mOVA(6) Tg mouse ears On maturation, LCs emigrate from the epidermis with the help of inflammatory cytokines such as tumor necrosis factor-a and IL-1b (Cumberbatch et al., 1997; Stoitzner et al., 1999) . Given the activation of LCs on day 2, OT-I cells were extracted directly from the dermis of the K14-mOVA(6) Tg mouse ears on day 2 after i.d. injection. CFSE-labeled OT-I cells proliferated (Figure 4a-d) and the OT-I cells exhibited upregulation of the CD69 activation marker (Figure 4e) . Interestingly, the draining LN of the injected K14-mOVA(6) Tg mouse ear did not contain significant numbers of CFSE þ OT-I cells on day 2 in contrast to the draining LN of the control C57BL/6 mouse ear (Figure 4c and d) . Thus, it appears that OT-I cells are activated locally, presumably by resident skin APCs, rather than in draining LNs. To additionally test this hypothesis, we used GFP þ OT-I cells. An i.d. injection of 2 Â 10 6 GFP þ OT-I cells into the K14-mOVA(6) mouse ears showed that few GFP þ OT-I cells traveled to the draining LN in the first 72 hours, whereas most appear on day 14 ( Figure 4f ). In contrast, GFP þ OT-I cells readily appeared in control C57BL/6 mice in the draining LN at 6, 24, and 72 hours, and disappeared by day 14 in the absence of Ag stimulation. These results show that the GFP þ OT-I cells do not migrate to the draining LN in significant numbers in the K14-mOVA(6) Tg mice during the expected time period (B48 hours) required for T-cell priming in the LN (Mempel et al., 2004) . This is likely because of the proliferation of OT-I cells as they directly encounter an activating signal within the skin, and not in the draining LN, and thereby acquire effector function(s).
Conditional ablation of epidermal LCs does not abrogate local GVHD in K14-mOVA(6) Tg mice
To begin the assessment of contributions of resident skin APCs, K14-mOVA(6) Tg mice were crossed with Langerin-DTR Tg mice that express DTR under control of a Langerin promoter (12). K14-mOVA(6) Â Langerin-DTR double Tg mice were injected i.p. with 500 ng of DT to ablate LCs in the epidermis after 48 hours (Figure 5a and b) , as previously reported (Bennett et al., 2005) . OT-I cells were then i.d. injected 4 days after LC ablation, and the treated ears were harvested for hematoxylin and eosin staining, whereas untreated ears were stained with anti-MHC II antibody to verify complete ablation of LCs 5 days after OT-I injection (Figure 5c and e). On day 5 after i.d. injection of OT-I cells, LC-ablated K14-mOVA Â Langerin-DTR Tg mice developed local GVHD similar to DT-treated normal K14-mOVA(6) Tg controls (Figure 5g and h). These results indicate that conditional ablation of LCs does not abrogate local GVHD reactions.
Impairment of dDCs and ablation of epidermal LCs does not abrogate local GVHD in K14-mOVA(6) Tg mice Langerhans cell populations in the epidermis are radioresistant, in contrast to other DC subsets in mice (Merad et al., 2002) . Therefore, irradiation followed by Skin biopsies from all K14-OVA Tg mouse strains exhibited basal vacuolar changes, apoptotic keratinocytes, and lymphocytic infiltration characteristic of GVHD on day 7 after treatment. Scale bar is 100 mm.
www.jidonline.org 2807 transfer of CD45 congenic b 2 m) bone marrow cells results in hematopoietic chimeras with recipient-derived LCs and donor-derived DCs in the LNs, spleen, and dermis. As b 2 m cells do not express MHC I molecules and therefore cannot present OVA peptide to OT-I cells, Ag presentation by dermal and lymphoid APCs are impaired (Koller et al., 1990) . To determine the contribution of dDCs to the local GVHD reaction, hematopoietic chimeras of the K14-mOVA(6) Tg mice were established. After reconstitution with b 2 m bone marrow cells, mice were assessed for chimerization by FACS analysis of epidermal, dermal, LN, and spleen suspensions. The vast majority of the LCs from epidermal cell suspensions were recipient-derived (CD45.2) (Figure 6a ), whereas 490% of MHC II high cells from dermal cell suspensions ( Figure 6b ) and 498% of MHC II high cells in the LNs and spleen were donor-derived (CD45.1) (Figure 6c and d). Though not entirely depleted (approximately 10% of the dermal MHC II high cells remained recipient-derived as previously reported), the vast majority were replaced by donor-derived b 2 m cells (Bogunovic et al., 2006) . I.d. injection of OT-I cells into K14-mOVA(6) Tg mice, whose OVA-presenting capacity was limited to LCs (b 2 m-K14-mOVA(6)), resulted in a local GVHD reaction (Figure 7d ) similar to that seen in K14-mOVA(6) Tg mice chimerized with wild-type littermate (B6.SJL) bone marrow cells (BJ.SJL-K14-mOVA(6)) ( Figure  7c ). Therefore, b 2 m chimeras of K14-mOVA(6) Â Langerin-DTR Tg mice were generated to eliminate Ag presentation by all skin DCs. Surprisingly, the K14-mOVA(6) Â Langerin-DTR Tg mice that had been chimerized with b 2 m bone marrow and then treated with DT (LC-depleted) also developed local GVHD after OT-I injection ( Figure 7b ). These results indicate that skin DCs (LCs and dDCs) are not critical for the induction of local GVHD in K14-mOVA(6) Tg mice.
Depletion of LCs from K14-mOVA(6) Â Langerin-DTR Tg epidermal cells abrogates the induction of an MELR in the presence of OT-I cell stimulation
Given the unexpected result that the functional elimination of all skin DCs did not abrogate the GVHD reaction in vivo, the activation of OT-I cells was further investigated in vitro. K14-mOVA(6) Â Langerin-DTR Tg mice and littermate K14-mOVA(6) Tg mice were treated with 500 ng of DT i.p. After 48 hours, epidermal cell suspensions were prepared and LC depletion was verified. DT treatment resulted in 450-fold reduction in the percentage of MHC II þ LCs recovered from the epidermal cell suspensions after enrichment by gradient centrifugation (Figure 8j and k).
When either K14-mOVA(6) Tg or K14-mOVA(6) Â Langerin-DTR Tg epidermal cell suspensions, not enriched for LCs, were cultured with CFSE-labeled OT-I cells, the OT-I cells proliferated ( (e) day 2, (f) day 3, and (g) day 4. Characteristic basal vacuolar changes, apoptotic keratinocytes, and lymphocytic infiltration were clearly evident by day 3. Epidermal sheets were separated from mouse ears and stained for MHC II molecules (400 Â ) on day 4 after i.d. injection of 2 Â 10 6 OT-I cells into (h) C57BL/6 mice and (i) K14-mOVA(6) Tg mice. The K14-mOVA(6) Tg mice exhibited widespread MHC II molecule expression on keratinocytes in a manner not observed in control C57BL/6 mice. Epidermal sheets were separated from mouse ears and stained for MHC II ( Â 400) on day 3 in C57BL/6 mice i.d. injected with (j) 20 ml of PBS or (k) 100,000 U of mIFN-g in 20 ml of PBS for 2 dyas. The mIFN-g-injected mice (k) exhibited widespread keratinocyte MHC II expression in a manner similar to K14-mOVA(6) mice after i.d. injection of OT-I cells (i) but not observed in control C57BL/6 mice (H). Scale bar is 100 mm.
control C57BL/6 or K14-mOVA(6) Â b 2 m Tg epidermal cells (Figure 8a and d). The latter control was used to rule out the possibility that contaminating DCs in the OT-I cell suspension could be responsible for cross-presentation of OVA Ag directly to the OT-I cells. Furthermore, both K14-mOVA(6) Tg and K14-mOVA(6) Â Langerin-DTR Tg epidermal cells (Figure 8f and g) induced IFN-g production by the OT-I cells and upregulation of CD25, CD44, and CD69 activation markers in contrast to that induced by control C57BL/6 and K14-mOVA(6) Â b 2 m Tg epidermal cells (Figure 8e , h-i). However, these same LC-depleted K14-mOVA(6) Â Langerin-DTR Tg epidermal cells that induced OT-I proliferation (Figure 9a) did not induce an MELR when cultured with allogeneic BALB/c T cells (Figure 9b ). These results indicate that OVAexpressing keratinocyte suspensions, in the absence of skin DCs, can directly prime OT-I cells. We used two other methods to verify that skin DCs were dispensable for Ag presentation. The first method involved harvesting keratinocytes from neonatal K14-mOVA(6) Tg mouse epidermis and eliminating the vast majority of LCs by repeated depletion using an AutoMACS separator (Miltenyi Biotech, Boston, MA) after incubating with MHC II microbeads. Using this method, the percentage of LCs in the epidermal cell suspensions was reduced to approximately . Autoreactive T-cell proliferate, are activated, and remain in the dermis of K14-mOVA(6) Tg mice on day 2 after i.d. injection. Naive OT-I cells were labeled with CFSE dye and i.d. injected at a dose of 2 Â 10 6 cells into the ears of K14-mOVA(6) Tg mice and control C57BL/6 mice. The dermal OT-I cells were extracted on day 2 for FACS analysis and proliferated in the (a) K14-mOVA(6) Tg mice but not in the (b) control C57BL/6 mice . The draining LNs were also harvested on day 2 for FACS analysis and the CFSE þ non-proliferating OT-I cells were readily detectable in the LN of (d) control C57BL/6 mice but few cells were present in LNs of (c) K14-mOVA(6) Tg mice. Cells were gated on CFSE þ /CD8 þ cells. GFP þ OT-I cells were also i.d. injected at a dose of 2 Â 10 6 cells into K14-mOVA(6) Tg mice and control C57BL/6 mice, and the dermal OT-I cells were extracted on day 2 for FACS analysis.
(e) The GFP þ OT-I cells in the K14-mOVA(6) Tg mice expressed enhanced amounts of CD69 on day 2 compared with those injected into C57BL/6 mice.
(f) GFP þ OT-I cells were i.d. injected at a dose of 2 Â 10 6 cells into K14-mOVA(6) Tg and control C57BL/6 mice and draining LN OT-I cells were harvested at 6, 24, and 72 hours, and on day 14. Few GFP þ OT-I cells were detected in the LNs of K14-mOVA(6) Tg mice in contrast to control C57BL/6 mice at 6, 24, and 72 hours. On day 14, GFP þ OT-I cells were readily detected in the LNs of K14-mOVA(6) Tg mice but not in control C57BL/6 mice.
www.jidonline.org 2809 0.001% following three rounds of depletion through the AutoMACS separator (Figure 10a ). Despite this marked depletion of MHC II þ cells from the neonatal K14-mOVA(6) Tg epidermal cell suspensions, OT-I cell proliferation ensued when incubated with these cells (Figure 10b ). As shown with the K14-mOVA(6) Â Langerin-DTR depleted of LCs using DT, the LC-depleted neonatal K14-mOVA(6) Tg epidermal cells also did not elicit an MELR when cultured with allogeneic BALB/c T cells after depletion through the AutoMACS separator (Figure 10c) .
The second method involved culturing primary neonatal keratinocytes from K14-mOVA(6) mice in low calcium medium and selectively removing the supernatant to reduce the number of LCs in the suspension. This method allows for the proliferating keratinocytes to remain adherent to the Petri dish for retrieval, whereas the LCs in suspension are eliminated. By this method, the percentage of LCs in the epidermal cell suspensions was reduced to approximately 0.26% after 3 days of culture (data not shown). Whether the initial keratinocyte suspension placed into culture was nondepleted (crude) or depleted of LCs using the AutoMACS separator, the reduction in the number of LCs was sufficient to abrogate an MELR when cultured with allogeneic BALB/c T cells in the presence of OT-I cell stimulation (data not shown). Furthermore, these keratinocyte suspensions induced an activated cell-surface phenotype on the OT-I cells with upregulation of CD25, CD44, and CD69, and downregulation of CD62L (data not shown). These additional results, using different methods, further support the conclusion that keratinocytes can directly present OVA peptide and induce an OT-I cell response.
DISCUSSION
In this localized GVHD model, OT-I cells elicit skin GVHD reactions after i.d. injection of OVA-reactive CD8 cells (OT-I) into Tg mice that express OVA in epidermal keratinocytes. We used this model to investigate the in vivo and in vitro contribution of skin DCs (LCs and dDCs) to present epidermal Ag by conditional ablation of epidermal LCs and impairment of MHC I presentation on dDCs. Unexpectedly, the elimination of LCs and the impairment of dDCs did not abrogate localized GVHD reactions. In addition, using two different methods of cell preparation, a 499% reduction in the number of LCs in vitro completely abrogated the induction of MELRs without attenuating the priming of OT-I cells by the same OVA-expressing epidermal cells. These results strongly suggest that keratinocytes expressing endogenous tissue Ags (OVA) can directly prime naive T cells (OT-I cells). Langerhans cells have traditionally been considered the primary APCs involved in the initiation of T-cell responses in the skin (Silberberg-Sinakin et al., 1976; Silberberg-Sinakin and Thorbecke, 1980; Macatonia et al., 1987) . Previous studies have implicated LCs as critical mediators of allogeneic GVHD and CD8 þ T-cell responses to epidermal selfAg (Mayerova et al., 2004; Merad et al., 2004) . More complex models using murine Herpes simplex virus and Leishmania have suggested that LCs do not have a significant role in Ag presentation (Allan et (Cunningham and Noble, 1989; Nickoloff et al., 1993) . However, these studies involved a mixed population of responder CD4 þ and CD8 þ T cells and the authors postulated that the immune response was initiated by the priming of CD4 þ T cells. It is more commonly believed that, owing to the absence of costimulatory molecules, the presentation of Ag by keratinocytes, particularly in the steady state, induces CD4 þ T-cell anergy rather than priming Bal et al., 1990) . In this study, we sought to investigate these questions using an in vivo model with a defined self-Ag (OVA) expressed in the epidermis and using a specified monoclonal population of CD8 þ T cells (OT-I cells). To examine the role of LCs in the cross-presentation of epidermal OVA, we crossed the K14-mOVA(6) Tg mice onto a Langerin-DTR Tg background (Bennett et al., 2005) . Interestingly, after the ablation of LCs with DT, the K14-mOVA(6) Â Langerin-DTR Tg mice still developed local GVHD with i.d. injection of OT-I cells. These results are consistent with the lack of abrogation of CHS observed in previous studies using DT-based technology to ablate LCs , 2005) . However, these studies did not examine the effects of impairing dDCs on CHS.
To identify the role of dDCs in the cross-presentation of epidermal OVA, we generated bone marrow chimeras that have MHC I-deficient (b 2 m) dDCs in the K14-mOVA(6) mice. This was done because of the striking systemic GVHD phenotype that we previously reported in this particular strain (Shibaki et al., 2004) . Lethally irradiated mice reconstituted with donor b 2 m bone marrow retain recipient LCs while allowing for the impairment of MHC I-dependent Ag presentation by dDCs (Merad et al., 2002) . Despite the impairment of cross-presentation by MHC I molecules in the dermis, LN, and the spleen, these mice developed local GVHD after i. To better assess the mechanism by which GVHD occurred in vivo despite the functional elimination of skin DCs, epidermal cells from LC-depleted K14-mOVA(6) Â Langerin-DTR Tg mice were cultured with OT-I cells in vitro. Interestingly, despite the drastic reduction of LCs (450-fold) in the epidermal cells, OT-I cells were still stimulated (proliferated, activated, and acquired effector function) to a similar degree as when mixed with littermate control K14-mOVA(6) Tg epidermal cells. Furthermore the LC-depleted epidermal cells could not induce a MELR, suggesting that the reduction in LCs was sufficient to abrogate other modes of physiologically relevant APC-dependent responses. These striking in vitro results corroborate the in vivo findings that despite the impairment or elimination of almost all skin DCs, GVHD ensues because of the underlying accessory cell function of keratinocytes. These results are further reinforced by a recent study showing that LCs in the skin are not required for skin graft rejection in mice mismatched for MHC Ags. In fact, it appears that the lack of LCs may even enhance graft rejection in mice mismatched for minor histocompability Ags (Obhrai et al., 2008) .
Accessory cell function of keratinocytes has recently been addressed specifically with regard to MHC I-specific presentation to a population of CD8 þ T cells. In contrast to the findings reported in our study, Stoitzner et al. (2006) showed that LCs rather than keratinocytes present endogenous epidermal OVA to OT-I cells using a similar K14-OVA Tg mouse model. Indeed, we also found that purified LCs can induce CD8 T-cell (OT-I) proliferation. In their study, Stoitzner et al. (2006) used 3-day cultured cells that were sorted according to the presence or absence of MHC class II positivity. The MHC class II À cells (keratinocytes) from their K14-OVA peptide Tg mice did not induce T-cell proliferation. However, as the data for these experiments were ''not shown,'' no comparison can be made between their experimental procedures as well as data and this study. Furthermore, the data to which they refer relate only to the K14-OVA SIINFEKL peptide mice that differ from our Tg mice that are Tg for a large segment of the OVA protein (9). In our study, we report that keratinocytes directly present self-Ag to CD8 þ T cells to induce priming. This was shown using two markedly different systems -DT-mediated depletion of DTRexpressing LCs and depletion of LCs from neonatal keratinocyte suspensions using MHC II microbeads. Whether this process is dependent on costimulatory molecules or is simply because of the high density of self-peptide on MHC I complexes remains to be elucidated. Furthermore, these findings do not preclude the role of LCs or dDCs in these reactions under normal physiological conditions. Keratinocytes have been reported to directly activate autoreactive CD4 T cells in the context of tissue inflammation (Fan et al., 2003) . In this study, Fan et al. (2003) propose that an inflammatory stimulus mobilizes IL-1 and/or tumor necrosis factor-a to induce the upregulation of MHC molecules on the surface of keratinocytes to allow them to act as primary APCs. It is possible that the inflammation associated with i.d. injection creates a similar context in which keratinocytes can act as APCs to present OVA Ag directly to OT-I cells. Nonetheless, our studies show, for the first time, that naive autoreactive CD8 T cells can be directly primed by keratinocytes in an Agspecific manner.
There remains the possibility that very small numbers of dermal DCs are sufficient to induce the priming of OT-I cells even in the absence of detectable allostimulation. However, given the fact that T cells respond in a dose-dependent manner to the number of stimulator DCs, if such were the case, we would still expect a drastic reduction in the OT-I cell response after depletion of LCs and this is not observed. We previously reported that approximately 1,000 migratory LCs from skin explants of K14-mOVA(6) Tg mouse ears were required to induce a minimal detectable level of OT-I cell proliferation in vitro and only at 10,000 stimulator LCs was a significant level of proliferation observed (Shibaki et al., 2004) . A generous approximation would suggest that the LCdepleted epidermal cell suspensions contain B100 remaining stimulator LCs after DT treatment, in contrast to B5,000 stimulator LCs in the undepleted epidermal cell suspensions. For the neonatal epidermal cell suspension, the number of remaining stimulator LCs would be even lower on the order of B1-2 cells after depletion with MHC II microbeads and the AutoMACS separator. Thus, it seems highly unlikely that such small numbers of OVA-bearing LCs could induce such robust priming of naive OT-I cells.
In summary, we have developed an efficient i.d. injection model whereby a local GVHD reaction can be elicited in multiple strains of K14-OVA Tg mice that express both soluble and membrane-bound forms of OVA at different levels of expression. This model provides a novel approach to study the mechanisms underlying the presentation of epidermally expressed self-Ag by specific populations of skin-resident cells. We have shown both in vivo and in vitro, by the elimination of skin DCs, that keratinocytes can function as accessory cells even in the absence of functional APCs. In addition to gaining mechanistic insights, we believe that this is an effective method by which to test potential therapies, both topical and systemic, that modulate cellmediated skin diseases.
MATERIALS AND METHODS
Mice
All K14-OVA Tg mouse lines were obtained from the National Cancer Institute Animal Production Program (Frederick, MD), housed in a clean (not pathogen-free) facility that does not allow MHV or pinworms, and were bred and used with institutional approval. OT-I Â RAG-1-deficient mice were purchased from Taconic (Germantown, NY) and UBI-GFP/BL6 mice were purchased from The Jackson Laboratory (Bar Harbor, ME).
Generation of Tg mice
The generation of the K14-mOVA(6) Tg mouse expressing membrane-associated OVA under a K14 promoter was previously described (Shibaki et al., 2004) . The K14-mOVA(3) Tg mouse was generated in the same manner. The Tg mice (K14-sOVA(5), , and K14-sOVA(17 Tg)) expressing soluble OVA (sOVA) were prepared by excising the OVA fragment (100-1167) from the TC-OVA plasmid (Lim et al., 1998) with BgIII and BamHI. The vector sequence encoding b-galactosidase was excised from a K14-bgal plasmid (Shibaki et al., 2004) with NotI and subsequently replaced with the OVA fragment by blunt-end ligation with T4 polymerase to make the pK14-sOVA plasmid. The sOVA plasmids do not contain the PDGFR, HA, or Myc sequences. All subsequent steps were the same as for the generation of the K14-mOVA Tg mouse lines. 
I.d. injection of OT-I cells
Single-cell suspensions were prepared from LNs of OT-I Â RAG-1-deficient or F1 (GFP þ Â OT-I) mice, further purified for CD8 þ cells using CD8 columns (R&D Systems, Minneapolis, MN), and resuspended in RPMI with 5% fetal calf serum. Before injection, 2 Â 10 6 OT-I cells were resuspended in 20 ml of PBS and injected intradermally into the left ears of K14-OVA Tg, K14-OVA Â Langerin-DTR Tg, control C57BL/6, or x-irradiated bone marrow-reconstituted chimeric mice. The mice were anesthetized by i.p. injection of 50 mg xylazine (Phoenix Pharmaceuticals, Burlingame, CA) and 2.5 mg of ketamine (Fort Dodge, Madison, NJ) in 250 ml of PBS just before the i.d. injection.
Preparation of epidermal sheets and fluorescent microscopy
Epidermal sheets were prepared as previously described (Caughman et al., 1986) and stained with mouse-anti-I-A b followed by secondary fluorescein-conjugated IgG Fab 0 2 fragments of goat-anti-mouse IgG (Biosource, Bethesda, MD). Images were captured using a Nikon Eclipse TE300 camera and IPLab software (Tokyo, Japan). An i.d. injection of mIFN-g (Peprotech, Rocky Hill, NJ) was performed at a dose of 100,000 U in 20 ml of PBS once a day for 2 days and epidermal sheets were prepared on day 3.
Histological analyses
Ear samples were prepared from K14-OVA Tg mice at various times after i.d. injection of OT-I cells and fixed in 10% neutral-buffered formalin. Paraffin-embedded tissues were sectioned and stained with hematoxylin and eosin using standard techniques (American Histolabs, Rockville, MD).
Flow cytometry
For monitoring T-cell proliferation, 2 Â 10 6 CFSE-labeled OT-I cells were i.d. injected into the left ears of recipient K14-OVA Tg mice. On day 2 after i.d. injection, CFSE-labeled OT-I cells were harvested from the left cervical LNs and from the dermis (see below) and stained with APC-conjugated anti-CD8 mAbs for FACS analysis. For monitoring of T-cell migration, 2 Â 10 6 OT-I cells isolated from F1 (GFP þ Â OT-I) mice were i.d. injected into the left ears of recipient K14-OVA Tg mice. At 6, 12, 24, 48, 72 hours, and 14 days, the left cervical LNs were harvested and stained with biotin-conjugated anti-Vb5 mAbs. APC-conjugated streptavidin was used for visualization of the biotinconjugated mAb. For staining of activation markers, phycoerythrinconjugated and APC-conjugated anti-CD25, -CD44, -CD62 L, -CD69, and isotype control antibodies were used. Experiments were performed on an FACSCalibur (San Jose, CA) and analyzed using CellQuest software (Becton Dickinson, Franklin Lakes, NJ).
Dermal extraction of OT-I cells
Autoreactive T cells were extracted from the dermis by mechanically splitting the dorsal and ventral halves of mouse ears on day 2 after i.d. injection. The split ears were then floated on a solution of 0.50 mg/ml Liberase CI (Roche Applied Science, Branford, CT) in RPMI for 1 hour at 37 1C and the dermis was mechanically scraped into the Liberase CI suspension. The suspension was diluted in RPMI with 5% fetal calf serum and 0.05% DNase and then filtered through a 70 mm filter. The recovered cells were then washed once in PBS with 5% fetal calf serum and stained with antibodies for FACS analysis.
Generation of x-irradiated bone marrow-reconstituted chimeras
Seven-to eight-week-old recipient CD45.2 þ C57BL/6, K14-mOVA(6), or K14-mOVA(6) Â Langerin-DTR mice were lethally irradiated (9 Gy) and reconstituted by i.v. injection of 1 Â 10 7 bone marrow cells from CD45.1 þ B6.SJL or b 2 m mice. Eights weeks after transplantation, ears, cutaneous LNs (CLNs), and spleens were harvested. Ears were split into dorsal and ventral halves and incubated in 0.5% trypsin and EDTA (5 mM) in PBS (Gibco, Carlsbad, CA) for 60-90 minutes at 37 1C to allow for separation of epidermal and dermal sheets. Epidermal sheets were made into a single-cell suspension and isolated by Lympholyte-M (Cedarlane, Burlington, NC) gradient. Dermal sheets were further incubated in 0.5 mg/ml Collagenase IA (Sigma, St Louis, MO) and 0.05% DNase (Sigma) and made into a single-cell suspension. LNs and spleens were made into single-cell suspensions. All cells were stained with various combinations of the following antibodies (BD Pharmingen, San Diego, CA): FITC-conjugated anti-CD45.1, CD45.2, and isotype mouse IgG2a; phycoerythrin-conjugated or APC-conjugated anti-I-A/I-E.
Depletion of LCs from K14-mOVA(6) Â Langerin-DTR Tg mice Diphtheria toxin (BIOMOL, Plymouth Meeting, PA) was reconstituted with sterile distilled water at a concentration of 2.5 ng/ml and injected at a dose of 500 ng i.p. Depletion of LCs was verified by immunofluorescence staining of epidermal sheets as described above.
Depletion of LCs from neonatal K14-mOVA(6) Tg mice
Primary keratinocytes were isolated from neonatal (days 1 to 3) K14-mOVA(6) Tg and C57BL/6 whole mouse skin as previously described (Steinman and Nussenzweig, 2002 Primary keratinocytes from neonatal (days 1 to 3) K14-mOVA(6) Tg and C57BL/6 mice were cultured in Eagle's minimal essential medium supplemented with 0.05 mM calcium chloride and 10% Chelex (Sigma)-treated fetal bovine serum (Hyclone, Logan, UT) in flat-bottom 96-well plates (1 Â 10 5 cells per well) for 3 days as previously published (Steinman and Nussenzweig, 2002) . The supernatants were removed and the adherent keratinocytes were harvested by trypsinization and mixed with OT-I and BALB/c T cells for proliferation assays. The OT-I and BALB/c T-cell suspensions were also depleted of MHC II þ cells using MHC II microbeads and the AutoMACS separator and quantified by FACS analysis.
In vitro proliferation assays
Adult epidermal cells were prepared from littermate K14-mOVA(6) Tg, K14-mOVA(6) Â Langerin-DTR Tg, K14-mOVA(6) Â b 2 m Tg, and C57BL/6 mice as previously described (Sauder et al., 1982) . Neonatal epidermal cells were prepared from K14-mOVA(6) Tg and C57BL/6 mice as previously described (Steinman and Nussenzweig, 2002) . Crude epidermal cells (1 Â 10 5 ) were added per well to a 96-well flat-bottom plate along with 5 Â 10 4 CFSElabeled OT-I cells. On day 3, the cells were harvested and stained with APC-conjugated anti-CD8 antibody and analyzed by FACS for proliferation. The same conditions were used to stain for activation markers of OT-I cells using the antibodies described above. Alternatively, 1 Â 10 5 crude epidermal cells were added per well to a 96-well flat-bottom plate along with 5 Â 10 4 unlabeled OT-I cells.
During the last 18 hours of the culture period 1 mCi of [ 3 H]TdR was added. On day 3, cells were harvested and cell-associated radioactivity was counted by direct b-counting using a gas ionization counter (Packard, Rockville, MD). For the MELRs, 4 Â 10 5 crude epidermal cells were added per well to a 96-well flat-bottom plate along with 2 Â 10 5 allogeneic BALB/c T cells or syngeneic C57BL/6 T cells isolated by a mouse T-cell enrichment column (R&D Systems). During the last 18 hours of the culture period, 1 mCi of [
